ATXI
Income statement / Annual
Last year (2024), Avenue Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Avenue Therapeutics, Inc.'s net income was -$11.65 M.
See Avenue Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$6.65 M
|
$10.36 M
|
$2.70 M
|
$1.25 M
|
$2.87 M
|
$23.19 M
|
$17.70 M
|
$7.80 M
|
$1.38 M
|
$4.00 M
|
| General & Administrative Expenses |
$4.64 M
|
$4.18 M
|
$5.35 M
|
$2.48 M
|
$2.35 M
|
$0.00
|
$4.12 M
|
$3.62 M
|
$997.00 K
|
$918.55 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.64 M
|
$4.18 M
|
$5.35 M
|
$2.48 M
|
$2.35 M
|
$3.07 M
|
$4.12 M
|
$3.62 M
|
$997.00 K
|
$842.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$175.00 K
|
-$99.00 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$11.28 M
|
$14.54 M
|
$8.04 M
|
$3.74 M
|
$5.21 M
|
$26.27 M
|
$21.82 M
|
$6.70 M
|
$2.38 M
|
$4.84 M
|
| Cost And Expenses |
$11.28 M
|
$14.54 M
|
$8.04 M
|
$3.74 M
|
$5.21 M
|
$26.27 M
|
$21.82 M
|
$11.42 M
|
$2.38 M
|
$4.84 M
|
| Interest Income |
$176.00 K
|
$126.00 K
|
$20.00 K
|
$7.00 K
|
$62.00 K
|
$357.00 K
|
$93.00 K
|
$88.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$1.16 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$375.00 K
|
$612.00 K
|
$417.82 K
|
| Depreciation & Amortization |
$0.00
|
$14.54 M
|
$0.00
|
$3.74 M
|
$0.00
|
$0.00
|
$21.82 M
|
$11.42 M
|
$2.38 M
|
$5.28 M
|
| EBITDA |
-$11.70 M |
$4.05 M |
-$2.44 M |
$7.00 K |
-$5.15 M |
-$25.91 M |
$0.00 |
$0.00 |
-$188.00 K |
$440.27 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$413.00 K
|
$4.05 M
|
$4.44 M
|
$7.00 K
|
$62.00 K
|
$357.00 K
|
$268.00 K
|
-$837.00 K
|
-$800.00 K
|
-$383.00 K
|
| Income Before Tax |
-$11.70 M
|
-$10.49 M
|
-$3.60 M
|
-$3.73 M
|
-$5.15 M
|
-$25.91 M
|
-$21.55 M
|
-$12.26 M
|
-$3.18 M
|
-$5.23 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$268.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$11.65 M
|
-$10.38 M
|
-$3.55 M
|
-$3.73 M
|
-$5.15 M
|
-$25.91 M
|
-$21.55 M
|
-$12.26 M
|
-$3.18 M
|
-$5.23 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.9 |
-73.6 |
-121.91 |
-3.29 |
-4.65 |
-24.38 |
-31.17 |
-27.71 |
-5.39 |
-9.4 |
| EPS Diluted |
-0.9 |
-73.48 |
-121.91 |
-3.29 |
-4.65 |
-24.38 |
-31.17 |
-27.71 |
-5.39 |
-9.4 |
| Weighted Average Shares Out |
$12.95 M
|
$141.00 K
|
$29.14 K
|
$1.13 M
|
$1.10 M
|
$1.05 M
|
$682.61 K
|
$442.33 K
|
$589.43 K
|
$556.10 K
|
| Weighted Average Shares Out Diluted |
$12.95 M
|
$141.22 K
|
$29.14 K
|
$1.13 M
|
$1.10 M
|
$1.05 M
|
$682.61 K
|
$442.33 K
|
$589.43 K
|
$556.10 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
